Prognostic significance of BMI after PCI treatment in ST-elevation myocardial infarction

A cohort study from the Swedish Coronary Angiography and Angioplasty Registry

Shabbar Jamaly MD, PhD^{1,3}, Björn Redfors MD, PhD^{1,3}, Elmir Omerovic MD, PhD^{1,3} Lena Carlsson³ MD, PhD², and Kristjan Karason MD, PhD^{1,2,3}

¹Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

²Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

³Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

Total word count: (abstract: 250, manuscript: 2041)

Brief title: Obesity paradox and PCI in STEMI

Key words: Obesity, BMI, Obesity paradox, co-morbidities, ST-elevation infarction (STEMI), percutaneous coronary intervention (PCI), All-cause mortality

Address for correspondence:

Dr Shabbar Jamaly

Department of Cardiology, Sahlgrenska University Hospital 41345 Gothenburg Sweden

Telephone: +46 31 342 10 0

Email: shabbar.jamaly@vgregion.se

CLINICAL TRIAL REGISTRATION: NCT02311231

Abstract

Background

Obesity along with clustering of cardiovascular risk factors is a promoter for coronary artery disease. On the other hand, a high BMI appears to exert a protective effect with respect to outcomes after a coronary artery event, termed the obesity paradox.

Methods

The Swedish Coronary and Angiography and Angioplasty registry (SCAAR) collects information on all patients who undergo percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) in Sweden along with demographic- and procedure-related data. We studied the predictability of four categories of BMI for 1-year all-cause mortality in people with STEMI undergoing PCI.

Results

Among 25,384 patients, mean (SD) age 67.7 (12.1) years and 71.1% male, who underwent PCI for STEMI a total of 5,529 (21.8%) died within one year. Using normal-weight (BMI 18.5-24.9 kg/m²) as a reference, subjects with obesity (BMI ≥30 kg/m²) had a low 1-year all-cause mortality risk in unadjusted analysis, HR 0.59 (95% CI 0.53– 0.67). However, after adjustment for age, sex and other covariates the difference became non-significant, HR 0.88 (95% CI: 0.75- 1.02). Patients with overweight (BMI 25.0-29.9 kg/m²) had the lowest 1-year mortality risk in analysis adjusted for age, sex and other covariates, HR 0.87 (95% CI 0.79-0.95), whereas those with underweight (BMI <18.5 kg/m²) had the highest mortality in both unadjusted HR 2.22 (95% CI 1.69–2.92) and adjusted analysis, HR 1.72 (95% CI: 1.31-2.26).

Conclusion

The protective effect of obesity with respect to 1-year mortality after coronary intervention became non-significant after adjusting for age, sex and relevant co-variables. Instead, overweight people displayed the lowest risk and underweight individuals the highest risk for adjusted all-cause mortality

Introduction

Obesity, together with associated clustering of cardiovascular risk factors, such as hypertension (1) dyslipidemia (2) and diabetes (3), is a strong promoter for cardiovascular disease morbidity and mortality (4-6). Weight control is considered to be of fundamental importance in primary prevention aimed at reducing the overall incidence of cardiovascular disease (7) and is also targeted in secondary preventive programs intended to improve outcome in patients with established cardiovascular disease (8, 9).

Still, a certain hesitancy has arisen concerning the beneficial effects of weight loss as a secondary prevention practice, since several epidemiologic have suggested that obesity may be protective in patients with coronary artery disease undergoing intervention (10-12). The apparent favorable effect of obesity on outcomes after coronary interventions, known as the “obesity paradox”, has generated a substantial amount of controversy (13). A protective effect of excess body fat is somewhat counter-intuitive and a mechanism involving reverse causality has been suggested (14). Also, body fat distribution, cardiorespiratory fitness and unintentional weight loss could constitute confounders accounting for the somewhat paradoxical relationship between obesity and prognosis after coronary intervention (15).

The aim of the present study was to evaluate the relationship between body fatness, divided up as four different body mass index (BMI) categories, and mortality in a large Swedish population undergoing percutaneous coronary intervention (PCI) due to an ST-elevation infarction (STEMI).

Patients and methods

Patient population

The Swedish Coronary and Angiography and Angioplasty Registry (SCAAR) was established in 1992 and contains information about all coronary angiographies and percutaneous coronary interventions (PCI) (formerly known as angioplasty with stent) (10). Each catheterization procedure is described with approximately 50 angiography and 200 PCI variables, including both demographic and procedure-related data. The registry is financed by the Swedish government and the Association of Local Authorities and Regions and is supported by the Swedish Heart Association, the National board of Health and Welfare and the Swedish Heart and Lung Foundation

All consecutive patients undergoing PCI for ST-elevation myocardial infarction (STEMI) in Sweden between January 1st 2011 and May 31st 2018 were included in the study. STEMI was defined according to the European Society of Cardiology criteria (16) as a condition when there is evidence of myocardial injury defined as a dynamic change in cardiac troponin values with at least one value above the 99th percentile upper reference limit, or a persistent chest discomfort suggestive of myocardial ischemia, along with an ST-segment elevation in at least two contiguous leads. Body weight and height, either measured or self-reported, were entered in the register at the time of the intervention. BMI, as a measure of nutritional status, was calculated as the weight in kilograms divided by the square of the height in meters. Other patient characteristics and information on co-morbidities were imported into the register from medical records. All patients admitted to the cardiac care unit are informed both, verbally and in writing about their participation in the registry. The regional ethical review board in Gothenburg approved the study. The investigation conforms with the principles outlined in the Declaration of Helsinki.

Outcome measures

The primary endpoints were mortality rates at 30 days and at 1 year. All Swedish citizens have a specific personal identity number that is recorded in connection with all health care contacts and makes it feasible to follow how the Swedish population interacts with the health care system. The SCAAR registry obtains data on patients' vital status from the Swedish Cause of Death Register, which originates from 1952 and includes the cause of mortality for all of citizens registered in Sweden at the time of their death (17).

Statistics

Statistical analyses were performed with SAS 9.4 statistical software packages (SAS Institute, Cary, NC). Study participants were divided into four categories according to their nutritional status as recommended by the World Health Organization (18): Underweight (BMI <18.5 kg/m²), normal weight (BMI 18.5-24.9 kg/m²), overweight (BMI 25.0-29.9 kg/m²) and obese (BMI ≥30.0 kg/m²). Data are presented for the total study population and for each BMI group separately as means and standard deviations, medians and interquartile ranges, or numbers and percentages. Comparisons between groups at baseline based on a complete case analysis were performed with analysis of variance (ANOVA) for normally distributed numeric data, Chi-Square test for categorical data and

Kruskal-Wallis rank sum test for non-normally distributed data. The number of complete cases with data for each variable is given as the dominators in **Table 1**.

For the first primary endpoint, participants were followed until death or for 30 days; and for the secondary primary end point, participants, were followed until death or up to 1 year. At these time points the SCAAR and Cause of Death Register were linked. Death is presented as a cumulative incidence function and comparison between groups was performed with the log rank test. Persons who emigrated or were alive at the end of the 1- or 12-month follow-up, respectively, were treated as censored observations. Death within the first 30 days was included as an event in the analysis for outcome at one-year follow-up, since we felt that that the risk for bias was low and, therefore, a landmark analysis redundant. Furthermore, since there were no competing events, it was not necessary to take this into account in the statistical analysis.

To evaluate the association between BMI categories and mortality, univariate and multivariable-adjusted hazard ratios (HR) were calculated using Cox proportional-hazards regression models. We performed a primary investigation employing a complete case analysis. Thereafter, to handle missing data, we performed a secondary examination after multiple imputation missing pattern [MIMP] with the missing at random (MAR) assumption. The first model was unadjusted; the second model was adjusted for age; the third model was adjusted for age and sex; and the fourth and final model was adjusted for all co-variables listed in **Table 1**. The reference group was defined as the normal nutritional category as defined by the WHO corresponding to a BMI of 18.5–24.99 kg/m². All models were specified prior to conducting analyses and adjusted for preselected baseline risk factors considered of importance for the outcome. Further, the causal directed acyclic graph approach (DAGs) was applied when adjusting for confounding. An adjusted mortality analysis for the first 30-days was also considered but, due to few events, we concluded that the study was underpowered for this. Penalized spline regression was applied to study relationship between BMI as a continuous variable and all-cause mortality. The likelihood ratio test was used to examine the consistency of the association between BMI categories and mortality in the following subgroups defined by baseline characteristics: males vs females, age > 65 years vs age ≤ 65 years; presence or absence of diabetes; and smokers vs non-smokers. All statistical tests were two-tailed and P-values of <0.05 were considered statistically significant.

Results

Patient characteristics

Between January 1st 2011 and May 31st 2018, a total of 25,384 patients underwent coronary artery catheterization for ST-elevation myocardial infarction at 29 PCI centers in Sweden. Among these, a total of 1304 (5.1%) died within 30 days of PCI and 5,529 (21.8%) died within one year after the intervention. Baseline characteristics for the total study group, and for different BMI categories separately, are presented in **Table 1**. People with obesity tended to be younger and have a more adverse cardiovascular risk factor profile with higher frequencies of hypertension, hyperlipidemia and diabetes as compared with those in other BMI categories, but were less often smokers than those who were underweight. Underweight patients were more often females, smoked more frequently and had a higher prevalence of chronic obstructive pulmonary disease (COPD). The angiographic burden of coronary artery disease and number of days hospitalized were similar among patients with different BMI categories.

Unadjusted 30-day and 1-year mortality in different BMI classes

Unadjusted *30-day* all-cause mortality for different BMI categories are presented with cumulative incidence curves in **Figure 1**. Patients who were underweight had the highest 30-day mortality (13.3%), followed by patients with normal weight (6.6%). Overweight and obese patients had somewhat lower cumulative mortality (4.3% and 4.2%, respectively). The overall log-rank p-value was <0.001.

Unadjusted *1-year* all-cause mortality for different BMI categories is presented with cumulative incidence curves in **Figure 2**. Again, there was a substantial difference in mortality between different BMI classes with the highest risk in the underweight group (23.3%) followed by those with normal weight (11.3%). Patients who were overweight or obese had a lower 1-year mortality risk (7.3% and 6.9%, respectively). The overall log-rank p-value was < 0.001.

Adjusted 1-year mortality in different BMI categories

Figure 3 presents a Forest plot of hazard ratios displayed in log-10 scale for *1-year* all-cause mortality in different BMI categories using the normal weight population as a reference group. People with underweight had the highest mortality compared with people of normal weight in both

unadjusted and multi-adjusted analysis. In contrast, patients with overweight had a lower mortality-risk compared with normal weight in both unadjusted and multi-adjusted analysis. Patients with obesity had a lower risk for death than normal weight subjects in unadjusted analysis, but this difference became non-significant in the multi-adjusted analysis considering age, sex and other covariates. Still the HR did not differ much from the overweight group and it is possible that the lack of significance is a type II statistical error.

In **Figure 4** we examined the association between BMI as a continuous variable and unadjusted and adjusted all-cause mortality using fractional polynomial Cox regression. In models adjusted for age and sex, the curves were U-shaped with a BMI/risk nadir between 25.0-29.9 kg/m². In the unadjusted and fully adjusted model the right side of the curve flattened with wide confidence intervals. In an interaction analysis, the relationship between BMI categories and risk of death was similar in subgroups of selected baseline characteristics (**Table 2**).

Discussion

In the present study, unadjusted statistical analysis showed that people with obesity (BMI ≥ 30.0 kg/m²) had the lowest 30-day and 1-year all-cause mortality after coronary intervention due to STEMI, when compared with the subjects of normal weight (BMI 18.5-24.99 kg/m²). Thus, in these analyses our results were in line with the obesity paradox. However, after adjustment for age and sex, the effect of obesity on mortality did not differ from that observed in people of normal weight. Instead, when age and sex had been considered, people with overweight (BMI 25-29.9 kg/m²) had the lowest mortality. In the one-year model adjusted for all covariates, people with overweight still had the lowest death rate, whereas the risk in people with obesity did not differ from that of those with normal weight. However, increasing BMI as a continuous variable in the fully adjusted one-year analysis, the risk curve flattened out with a wide confidence interval, making it difficult to interpret. Of notice, people with obesity do have a lower mortality in unadjusted analysis and did not display a higher mortality than those of normal weight in the fully adjusted model. On the other hand, people who were underweight (BMI <18.5 kg/m²) had a mortality that was substantially higher than that observed for other BMI classes.

Previous publications, including a report from the Framingham heart study (19), results from the Canadian APPROACH register (20) and data from the SCAAR register (12) showed that in patients

with established coronary artery disease, the lowest adjusted risk for mortality reached a nadir around a BMI of 35 kg/m². Furthermore, a meta-analysis by Wang and et al. (21) found lower all-cause mortality after myocardial infarction in a pooled group of overweight and obese subjects compared with people of normal weight. In contrast Shahim and coworkers (22) found no relationship between BMI and myocardial infarction size, or 1-year rates of death or heart failure hospitalization, in a meta-analysis based on 2,238 patients undergoing PCI.

The present study differed from the publications cited above regarding several aspects. Our patient population was considerably more homogenous compared with that in previous studies. The heterogeneity of previous study populations involved inclusion of patients undergoing PCI for STEMI, also subjects with NSTEMI treated with PCI or medication alone and in some cases management with coronary artery bypass grafting. Furthermore, in some of these studies patients with underweight were excluded and adjustment for covariables were not performed as they were not available. It is not unlikely that these differences may explain the main disparity between previous reports and the present study, which showed that the lowest risk for one-year all-cause mortality after adjusting for covariates was observed among overweight patients (BMI-range 25.0-29.9 kg/m²). Our findings are more in line with those of Flegal et al (23) who performed a metanalysis including 2.9 million people and observed that the overweight group had a trend for better survival as compared with those who were obese.

In the present study underweight individuals (BMI <18.5 kg/m²) displayed the highest risk for all-cause 30-day and 1-year mortality post-PCI in both unadjusted and adjusted statistical analyses. The separation between the mortality curves for the underweight group, as compared with other BMI categories, occurred early after PCI and, showed, thereafter, a steeper upward slope during one-year follow-up. We speculate that underweight patients may have an underlying pathophysiology that may generate a larger STEMI, more complications or impaired recoverability than subjects with a higher BMI. Also, previous epidemiological studies have observed a U-shaped relationship between BMI and all-cause mortality in the general population (24, 25). This has mainly been attributed to smoking (26), respiratory illnesses (27) and other underlying diseases (28). In the present study underweight patients were more often smokers and had a higher prevalence of chronic obstructive pulmonary disease (COPD). Thus, excessive mortality in underweight patients following PCI for STEMI could also be related to a higher occurrence of underlying co-morbidities.

The relationship between categories of BMI and outcome was consistent across all subgroups studied for selected baseline characteristics. Hence, there was no difference between the two sexes, those with age below or above 65 years, those with or without diabetes mellitus, or those who smoked and those who did not.

In a review from 2017, Lavie et al. (29) have listed several possible reasons or biases for the obesity paradox including younger patients, fewer smokers, better energy reserves, increased muscle mass and reverse epidemiology due to frailty and cachexia in patients that are leaner, apart from other and unknown confounders. Of notice is that BMI as a measure of obesity does not differ between fat, muscle mass and skeletal weight (30). It is highly probable that an augmented muscle mass may act as a protective factor with respect to outcome after coronary interventions (31). Lavie et al studied patients with stable coronary artery disease and found that those with a higher lean body mass had better survival irrespective of their degree of fatness (32). Thus, the importance of muscle mass as an explanatory mechanism of the obesity paradox has probably been underestimated. Also, cardiorespiratory fitness is an important variable that may greatly influence the relationship between obesity and survival after PCI (33).

Strengths and limitations

The strength of our study includes a large sample size of real-world data and a homogenous group of patients treated with PCI for ST-elevation myocardial infarction. The main limitation is the observational nature of the study, which precludes us from making any causal inferences. As only surviving hospitalized patients are included, the possibility of selection bias, residual confounding and survival bias cannot be ruled out. BMI as a measure of obesity, has its limitation as a measure of obesity since it does not distinguish between fat, muscle mass and skeletal weight. Neither waist circumference nor other measures of abdominal fatness were not available in the SCAAR register and, therefore, we were not able into account the distribution of body fat in our analyses. The role of unintentional weight loss was not controlled and cause-specific mortality data was not studied. Data on death was collected by crosslinking the SCAAR with the Swedish Cause of Death Register, which is a high quality virtually complete register of all deaths in Sweden since 1952, but is not adjudicated to establish cardiac versus non-cardiac causes of death.

Conclusions

Although people with obesity displayed lower mortality after treatment with PCI for STEMI as compared with a reference group with normal weight, the two groups showed similar outcomes after relevant covariates were considered. Assessed against the referent group, overweight patients showed the lowest 30-day and one-year adjusted mortality risk, and underweight individuals the highest. We speculate that the amount of muscle mass and cardiorespiratory fitness may affect the relationship between BMI and outcome in patients with coronary artery disease.

Contributorship Statement

Shabbar Jamly, MD, PhD. Conceptualization, investigation, methodology, project administration, visualization, supervision, validation and writing original draft. Review and editing. Overall content guarantor.

Björn Redfors MD, PhD. Conceptualization, data curation, formal analysis and software.

Lena Carlsson, MD, PhD. Writing -review and editing

Elmir Omerovic, MD, PhD. Conceptualization, data curation, writing- review and editing.

Kristjan Karason, M.D. Ph.D. Funding acquisition, writing -review and editing. Overall content guarantor.

Sources of Funding:

Research reported in this publication was funded by the Swedish federal government under the ALF agreement (ALFGBG-932636, ALFGBG-775351, ALFGBG-633141)

Disclosures

None of the authors has any conflicts of interest to declare with respect to the present study

References

1. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. *Circ Res*. 2015;116(6):991-1006.
2. Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. *Metabolism*. 2019;92:71-81.
3. Hossain P, Kavar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. *The New England journal of medicine*. 2007;356(3):213-5.
4. Suwaidi JA, Wright RS, Grill JP, Hensrud DD, Murphy JG, Squires RW, et al. Obesity is associated with premature occurrence of acute myocardial infarction. *Clinical cardiology*. 2001;24(8):542-7.
5. Zhu J, Su X, Li G, Chen J, Tang B, Yang Y. The incidence of acute myocardial infarction in relation to overweight and obesity: a meta-analysis. *Arch Med Sci*. 2014;10(5):855-62.
6. Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. *Jama*. 2012;307(1):56-65.
7. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur J Cardiovasc Prev Rehabil*. 2007;14 Suppl 2:E1-40.
8. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *European heart journal*. 2016;37(29):2315-81.
9. Delling L, Karason K, Olbers T, Sjostrom D, Wahlstrand B, Carlsson B, et al. Feasibility of bariatric surgery as a strategy for secondary prevention in cardiovascular disease: a report from the Swedish obese subjects trial. *Journal of obesity*. 2010;2010.
10. Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar-Zadeh K. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. *Obesity*. 2008;16(2):442-50.
11. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. *Lancet*. 2006;368(9536):666-78.

12. Angeras O, Albertsson P, Karason K, Ramunddal T, Matejka G, James S, et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. *European heart journal*. 2013;34(5):345-53.
13. Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or fiction? *The American journal of cardiology*. 2006;98(7):944-8.
14. Preston SH, Stokes A. Obesity paradox: conditioning on disease enhances biases in estimating the mortality risks of obesity. *Epidemiology (Cambridge, Mass)*. 2014;25(3):454-61.
15. Barry VW, Baruth M, Beets MW, Durstine JL, Liu J, Blair SN. Fitness vs. fatness on all-cause mortality: a meta-analysis. *Progress in cardiovascular diseases*. 2014;56(4):382-90.
16. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Rev Esp Cardiol (Engl Ed)*. 2017;70(12):1082.
17. Brooke HL, Talback M, Hornblad J, Johansson LA, Ludvigsson JF, Druid H, et al. The Swedish cause of death register. *European journal of epidemiology*. 2017;32(9):765-73.
18. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser*. 2000;894:i-xii, 1-253.
19. Oreopoulos A, McAlister FA, Kalantar-Zadeh K, Padwal R, Ezekowitz JA, Sharma AM, et al. The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. *European heart journal*. 2009;30(21):2584-92.
20. Powell BD, Lennon RJ, Lerman A, Bell MR, Berger PB, Higano ST, et al. Association of body mass index with outcome after percutaneous coronary intervention. *The American journal of cardiology*. 2003;91(4):472-6.
21. Wang L, Liu W, He X, Chen Y, Lu J, Liu K, et al. Association of overweight and obesity with patient mortality after acute myocardial infarction: a meta-analysis of prospective studies. *International journal of obesity*. 2016;40(2):220-8.
22. Shahim B, Redfors B, Chen S, Thiele H, Eitel I, Gkargkoulas F, et al. BMI, Infarct Size, and Clinical Outcomes Following Primary PCI: Patient-Level Analysis From 6 Randomized Trials. *JACC Cardiovascular interventions*. 2020;13(8):965-72.
23. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. *Jama*. 2013;309(1):71-82.
24. Kee CC, Sumarni MG, Lim KH, Selvarajah S, Haniff J, Tee GHH, et al. Association of BMI with risk of CVD mortality and all-cause mortality. *Public health nutrition*. 2017;20(7):1226-34.
25. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. *The New England journal of medicine*. 2010;363(23):2211-9.

26. Hjellevik V, Selmer R, Gjessing HK, Tverdal A, Vollset SE. Body mass index, smoking, and risk of death between 40 and 70 years of age in a Norwegian cohort of 32,727 women and 33,475 men. *European journal of epidemiology*. 2013;28(1):35-43.
27. Prospective Studies C, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet*. 2009;373(9669):1083-96.
28. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. *Jama*. 2007;298(17):2028-37.
29. Lavie CJ, Arena R, Alpert MA, Milani RV, Ventura HO. Management of cardiovascular diseases in patients with obesity. *Nature reviews Cardiology*. 2018;15(1):45-56.
30. De Schutter A, Lavie CJ, Patel DA, Artham SM, Milani RV. Relation of body fat categories by Gallagher classification and by continuous variables to mortality in patients with coronary heart disease. *The American journal of cardiology*. 2013;111(5):657-60.
31. Azimi A, Charlot MG, Torp-Pedersen C, Gislason GH, Kober L, Jensen LO, et al. Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. *Heart*. 2013;99(9):655-60.
32. Lavie CJ, De Schutter A, Patel DA, Romero-Corral A, Artham SM, Milani RV. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the "obesity paradox". *Journal of the American College of Cardiology*. 2012;60(15):1374-80.
33. McAuley PA, Smith NS, Emerson BT, Myers JN. The obesity paradox and cardiorespiratory fitness. *Journal of obesity*. 2012;2012:951582.

Figure legends

Figure 1. Thirty-day all-cause mortality after PCI in STEMI for different BMI categories

Figure 2. One-year all-cause mortality after PCI in STEMI for different BMI categories

Figure 3. Unadjusted and adjusted risk for mortality (95% CI) in patients with STEMI using log-10 scale for the X axis

Figure 4. Unadjusted and adjusted fractional polynomial Cox proportional hazards regression (95% CI, shaded area) with continuous risk relationship between BMI and all-cause mortality after PCI treatment for STEMI

Table 1. Baseline characteristics for the total study group and for the different BMI categories separately*

Characteristics	Total Group (n=25384)	Underweight (n=244)	Normal weight (n=8488)	Overweight (n=11132)	Obese (n=5520)	P-value
Age (years)	67.7 ± 12.1	74.8 ± 11.6	71.1 ± 12.0	67.1 ± 11.5	63.6 ± 11.7	<0.001
Weight (kg)	81.2 ± 16.0	48.2 ± 5.9	68.4 ± 9.2	82.7 ± 9.5	99.7 ± 14.5	<0.001
Height (cm)	172.9 ± 9.7	167.0 ± 8.9	172.2 ± 9.3	173.9 ± 8.9	172.3 ± 10.6	<0.001
Body Mass Index (kg/m ²)	27.2 ± 6.1	17.3 ± 1.1	23.0 ± 1.6	27.3 ± 1.4	33.8 ± 9.4	<0.001
Female sex	28.9% (7345/25384)	68.9% (168/244)	33.8% (2870/8488)	23.4% (2606/11132)	30.8% (1701/5520)	<0.001
Hypertension	49.0% (12221/24952)	43.8% (103/235)	43.9% (3648/8309)	48.6% (5330/10973)	57.8% (3140/5435)	<0.001
Hyperlipidemia	25.5% (6325/24792)	19.0% (44/231)	21.5% (1780/8266)	25.8% (2810/10899)	31.3% (1691/5396)	<0.001
Diabetes mellitus	16.2% (4095/25218)	7.5% (18/241)	11.3% (955/8427)	15.0% (1666/11072)	26.6% (1456/5478)	<0.001
Insulin-treated diabetes mellitus	7.0% (1756/25169)	3.7% (9/241)	4.7% (396/8413)	6.0% (666/11057)	12.6% (685/5458)	<0.001
S-creatinine (μmol/L)	92.4 ± 55.1	89.2 ± 65.8	92.4 ± 55.7	91.3 ± 50.9	92.0 ± 53.0	<0.001
eGFR <30ml/min/1.75m ²	1445 ± 5.7	24 ± 9.8	558 ± 6.6	576 ± 5.2	287 ± 5.2	<0.001
Previous renal failure	2.5% (640/25384)	2.9% (7/244)	2.7% (227/8488)	2.1% (237/11132)	3.1% (169/5520)	<0.003
Previous dialysis	0.4% (107/25384)	0.4% (1/244)	0.4% (37/8488)	0.4% (43/11132)	0.5% (26/5520)	0.88
Current smoker	28.6% (6880/24033)	41.4% (94/227)	29.9% (2388/7990)	27.0% (2857/10577)	29.4% (1541/5239)	<0.001
Previous COPD	5.3% (1355/25384)	21.3% (52/244)	6.4% (546/8488)	4.1% (456/11132)	5.5% (301/5520)	<0.001
Previous cancer diagnosis	2.3% (590/25384)	3.3% (8/244)	2.6% (222/8488)	2.2% (250/11132)	2.0% (110/5520)	0.07
Previous dementia	0.4% (96/25384)	1.6% (4/244)	0.4% (38/8488)	0.4% (43/11132)	0.2% (11/5520)	<0.001
Previous heart failure	4.4% (1120/25384)	6.6% (16/244)	4.7% (395/8488)	3.7% (414/11132)	5.3% (295/5520)	<0.001
Previous myocardial infarction	13.0% (3296/25384)	11.9% (29/244)	12.6% (1073/8488)	12.6% (1402/11132)	14.3% (792/5520)	<0.02
Previous PCI	10.8% (2750/25384)	7.4% (18/244)	9.7% (827/8488)	11.0% (1220/11132)	12.4% (685/5520)	<0.001
Previous CABG	2.9% (747/25384)	1.2% (3/244)	2.5% (214/8488)	3.0% (334/11132)	3.6% (196/5520)	0.002
Previous stroke	31.9% (7661/24033)	22.5% (51/227)	27.9% (2229/7990)	33.8% (3579/10577)	34.4% (1802/5239)	<0.001
Prior peripheral vascular disease	3.4% (864/25384)	11.9% (29/244)	4.1% (347/8488)	3.0% (335/11132)	2.8% (153/5520)	<0.001
Number of days hospitalized	4.0 [3.0, 5.0]	4.0 [3.0, 8.0]	4.0 [3.0, 6.0]	4.0 [3.0, 5.0]	4.0 [3.0, 5.0]	<0.001
Acute occlusion	60.9% (15460/25384)	54.1% (132/244)	60.4% (5129/8488)	61.4% (6830/11132)	61.0% (3369/5520)	0.46
Intraprocedural thrombosis	19.7% (4988/25376)	16.4% (40/244)	19.0% (1609/8487)	20.5% (2278/11128)	19.2% (1061/5517)	0.05
Successful procedure	95.3% (24017/25194)	91.5% (215/235)	95.2% (8016/8420)	95.8% (10595/11061)	94.8% (5191/5478)	0.85
Aspirin pre-cath lab	95.3% (24017/25194)	91.5% (215/235)	95.2% (8016/8420)	95.8% (10595/11061)	94.8% (5191/5478)	0.78
Clopidogrel pre-cath lab	19.0% (4814/25366)	18.9% (46/244)	19.3% (1638/8484)	19.4% (2153/11126)	17.7% (977/5512)	0.12
Ticagrelor pre-cath lab	58.1% (13800/23736)	54.6% (125/229)	56.9% (4515/7941)	58.5% (6077/10385)	59.5% (3083/5181)	0.19
Prasugrel pre-cath lab	4.1% (1032/25368)	2.9% (7/244)	4.0% (342/8484)	4.2% (465/11127)	4.0% (218/5513)	0.70
Warfarin pre-cath lab	2.1% (526/25368)	2.0% (5/244)	2.2% (185/8484)	2.0% (223/11127)	2.0% (113/5513)	0.86

*Data are presented as mean ± SD, percentages (numerator/denominator) or medians [interquartile ranges]

Table 2. Hazard ratios for the risk of mortality in subgroups.

Subgroups	BMI category	HR (95% CI)	P-value for interaction
Sex			
Male	Underweight	2.074 (1.272-3.383)	0.68
	Overweight	0.873 (0.756-1.008)	
	Obese	0.890 (0.730-1.084)	
Female	Underweight	1.394 (0.917-2.119)	
	Overweight	0.866 (0.721-1.039)	
	Obese	0.864 (0.691-1.082)	
Age			
Age > 65	Underweight	1.595 (1.140-2.230)	0.38
	Overweight	0.896 (0.794-1.011)	
	Obese	0.911 (0.771-1.076)	
Age ≤ 65	Underweight	1.964 (0.714-5.406)	
	Overweight	0.687 (0.495-0.952)	
	Obese	0.709 (0.492-1.023)	
Diabetes mellitus			
Diabetic	Underweight	2.591 (1.051-6.385)	0.62
	Overweight	0.937 (0.736-1.194)	
	Obese	0.877 (0.674-1.143)	
Non-diabetic	Underweight	1.535 (1.092-2.157)	
	Overweight	0.851 (0.748-0.968)	
	Obese	0.898 (0.745-1.082)	
Smoking			
Current smoker	Underweight	1.766 (1.017-3.066)	0.67
	Overweight	0.782 (0.611-1.001)	
	Obese	0.917 (0.674-1.249)	
Non-smoker	Underweight	1.550 (1.049-2.291)	
	Overweight	0.893 (0.786-1.015)	
	Obese	0.871 (0.733-1.034)	